Real-world characteristics of 'super-responders' to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
| Autor: | Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Santi Nolasco, Corrado Pelaia, Nunzio Crimi, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nicola Scichilone, Girolamo Pelaia, Claudia Crimi, Giovanna Elisiana Carpagnano |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | ERJ Open Research, Vol 9, Iss 5 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2312-0541 23120541 |
| DOI: | 10.1183/23120541.00419-2023 |
| Popis: | Background The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities. Although eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated with SEA, we lack data on a possible super-response to biologic treatments in patients suffering from these two diseases. We aim to assess super-responder features in real-life patients with SEA and EGPA treated with mepolizumab and benralizumab. Methods We enrolled 39 patients with SEA and EGPA eligible for treatment with mepolizumab or benralizumab. Super-responder assessment was performed considering oral corticosteroid (OCS) cessation, lack of exacerbations, forced expiratory volume in 1 s and Asthma Control Test (ACT) improvement. Results Super-responders showed worse clinical baseline characteristics than non-super-responder patients, with a greater improvement in severe asthma exacerbations, OCS dose reduction and ACT score increase. Definition of super-responders was consistent only considering a 12-month course of monoclonal antibody, lacking sensitivity in earlier evaluations. Conclusion Mepolizumab and benralizumab are safe and effective in patients with EGPA and SEA, since a consistent proportion of patients show a super-response after 12 months of treatment. Further studies will address specific criteria for super-responder assessment in these patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|